ARTICLE | Product Development
BioNTech fails to impress with early CAR T data at SITC
On deck for the mRNA play are data for BNT211 plus CARVac, which is expected to give the CAR T therapy an efficacy boost for solid tumors
November 10, 2021 12:43 AM UTC
BioNTech is reporting initial first-in-human data from several cancer programs at SITC, and so far, investors aren’t impressed by the mRNA company’s cancer data. The real proof of concept for one of its cancer platforms may not come until the company presents updated data at the conference.
Shares of BioNTech SE (NASDAQ:BNTX) dropped $16.23 to $226.37, leading to a loss in market cap of about $4 billion...